R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Related Videos

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

AGA Issues New Guideline Urging Risk-Based Surveillance in Barrett’s Esophagus

Local Consolidative Therapy Enhances Outcomes With Osimertinib in EGFR-Mutant NSCLC

Postsurgical ctDNA Testing in Stage III Colon Cancer for Treatment De-escalation

Clinical Usefulness of Linking Whole-Genome Data to Mortality Statistics in UK Patients With Breast Cancer

Obesity-Related Cancers Are Rising Among Both Younger and Older Adults Worldwide